Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade A 17.1 -0.47% -0.08
NVAX closed down 0.76 percent on Thursday, April 9, 2020, on 61 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical NVAX trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.29%
Inside Day Range Contraction 0.29%
Wide Bands Range Expansion 0.29%
Overbought Stochastic Strength 0.29%
New 52 Week Closing High Bullish -0.47%
Pocket Pivot Bullish Swing Setup -0.47%
Doji - Bearish? Reversal -0.47%
New 52 Week High Strength -0.47%
Wide Bands Range Expansion -0.47%
Gapped Up Strength -0.47%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Coronavirus Influenza Vaccination Vaccines Influenza Vaccine Rabies Seasonal Influenza H5n1 Clinical Trials Virus Like Particle

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.25
52 Week Low 3.54
Average Volume 7,830,531
200-Day Moving Average 6.39
50-Day Moving Average 10.49
20-Day Moving Average 12.75
10-Day Moving Average 14.97
Average True Range 1.84
ADX 37.27
+DI 39.09
-DI 13.38
Chandelier Exit (Long, 3 ATRs ) 12.73
Chandelier Exit (Short, 3 ATRs ) 12.29
Upper Bollinger Band 18.20
Lower Bollinger Band 7.31
Percent B (%b) 0.89
BandWidth 85.37
MACD Line 1.77
MACD Signal Line 1.41
MACD Histogram 0.3605
Fundamentals Value
Market Cap 4.94 Billion
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -22.14
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.61
Resistance 3 (R3) 18.70 18.28 18.35
Resistance 2 (R2) 18.28 17.88 18.23 18.26
Resistance 1 (R1) 17.66 17.63 17.45 17.57 18.18
Pivot Point 17.24 17.24 17.13 17.19 17.24
Support 1 (S1) 16.62 16.84 16.41 16.53 15.92
Support 2 (S2) 16.20 16.59 16.15 15.84
Support 3 (S3) 15.58 16.20 15.75
Support 4 (S4) 15.49